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Summary
Atypical 7-transmembrane receptors, often called decoy receptors, act promiscuously as molecular
sinks to regulate ligand bioavailability and consequently temper the signaling of canonical G
protein-coupled receptor (GPCR) pathways. Loss of mammalian CXCR7, the most recently
described decoy receptor, results in postnatal lethality due to aberrant cardiac development and
myocyte hyperplasia. Here, we provide the molecular underpinning for this proliferative
phenotype by demonstrating that the dosage and signaling of adrenomedullin (Adm = gene, AM =
protein)—a mitogenic peptide-hormone required for normal cardiovascular development—is
tightly controlled by CXCR7. To this end, Cxcr7−/− mice exhibit gain-of-function cardiac and
lymphatic vascular phenotypes which can be reversed upon genetic depletion of adrenomedullin
ligand. In addition to identifying a biological ligand accountable for the phenotypes of Cxcr7−/−
mice, these results reveal a previously underappreciated role for decoy receptors as molecular
rheostats in controlling the timing and extent of GPCR-mediated cardiac and vascular
development.
Introduction
The precise spatiotemporal dosage of mitogenic and chemotactic factors is critical for the
proper organization and development of organ systems. While the concentration of ligands
often differs between tissues and developmental stages, the bioavailability of ligands within
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local microenvironments must also be controlled at a cellular level. Thus, cells can express
molecular sink receptors, which in an autocrine or paracrine manner, sequester ligand away
from canonical signaling receptors, thereby driving important developmental processes like
neurogenesis, angiogenesis, chemotaxis and cellular proliferation (Graham et al., 2012;
Nibbs and Graham, 2013). Molecular sink receptors include atypical chemokine receptors,
also known as decoy receptors, which belong to the larger family of 7-transmembrane
receptors. Decoy receptors act as molecular sinks by binding, internalizing, and degrading a
wide range of ligands independent of G-protein coupling (Graham, 2012). CXCR7 is the
most recently described decoy receptor and has been extensively studied for its role as a
CXCL12/SDF-1 receptor (Boldajipour et al., 2008; Naumann et al., 2010; Thelen and
Thelen, 2008), particularly in tumor cell migration and cancer progression (Duda et al.,
2011; Sanchez-Martin et al., 2013).
However, prominent roles for CXCR7 during normal development and physiology have also
been recently appreciated. In zebrafish, the expression and molecular sink functions of
CXCR7 in trailing cells of the posterior lateral line primordium allows for a CXCL12
chemotactic gradient to be established and sensed by the leading primoridal germ cells
which express CXCR4, the canonical SDF-1/CXCL12 receptor (Dambly-Chaudiere et al.,
2007; Dona et al., 2013; Valentin et al., 2007; Venkiteswaran et al., 2013). In this instance,
CXCR7 exerts its decoy activities over a wide region to help coordinate and guide the
migration of multicellular tissue structures.
However, the decoy activities of CXCR7 can also occur in a cell-autonomous fashion. For
example, the co-expression of CXCR7 within migrating cortical neurons allows for the
continued sensitization and chemotactic signaling of CXCR4--rather than receptor
desensitization and downregulation that would typically occur within an environment of
high CXCL12 ligand (Sanchez-Alcaniz et al., 2011; Wang et al., 2011). Recently, CXCR7
expression in endothelial cells has also been shown to regulate circulating levels of ligands,
suggesting that CXCR7 expression in vessels may not only affect signaling events in a
microenvironment, but systemically as well (Berahovich et al., 2014).
Due to these well-described roles in the CXCL12/CXCR4 signaling axis, Cxcr7−/− mice
were expected to exhibit phenotypes that might resemble gain-of-function mutations for the
CXCL12/CXCR4 signaling axis. However, Cxcr7−/− mice have unexpected phenotypes
including cardiomyocyte hyperplasia and postnatal lethality associated with gross cardiac
enlargement and cardiac valve defects (Gerrits et al., 2008; Sierro et al., 2007; Yu et al.,
2011). Because decoy receptors typically bind and sequester multiple ligands, it has been
difficult to discern which ligand may be causally related to the developmental cardiac
defects of Cxcr7−/− mice. In this regard, we appreciated that CXCR7 was originally
identified as RDC1--a putative receptor for adrenomedullin (Adm = gene, AM = protein), a
52 amino acid mitogenic peptide hormone critical for cardiac and lymphatic vascular
development (Caron and Smithies, 2001; Dackor et al., 2006; Dunworth et al., 2008; Fritz-
Six et al., 2008). AM binds RDC1/CXCR7 with a Kd of 1.9 ×10−7 M, similar to CLR when
associated with RAMPs (Kapas and Clark, 1995). Importantly, we have recently shown that
genetic overexpression of AM ligand in Admhi/hi mice results in gross cardiac enlargement
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due to cardiac hyperplasia during embryogenesis (Wetzel-Strong et al., 2013), which closely
phenocopies the dysmorphic cardiac hyperplasia of Cxcr7−/− mice.
We therefore sought to address whether a principal function of CXCR7 may involve
controlling the dosage of AM ligand during development, first focusing our attention on the
cardiac hyperplasia. In the course of our studies, we also discovered lymphatic vascular
defects in Cxcr7−/− mice, which are consistent with the prominent role that AM signaling
plays in driving normal lymphangiogenesis (Dunworth et al., 2008; Fritz-Six et al., 2008;
Hoopes et al., 2012; Karpinich et al., 2011). In addition to identifying a biological ligand
that is causally associated with the Cxcr7−/− phenotypes, the results described here elucidate
a role for decoy receptors as molecular rheostats that control normal cardiac and lymphatic
vascular development.
Results
Gene expression of Cxcr7 and Adm are coupled in the heart and lymphatic endothelium
Historical ligand binding data (Kapas and Clark, 1995) and more recent findings showing a
down-regulation of Adm gene expression in Cxcr7−/− mice (Sierro et al., 2007), strongly
support the existence of this ligand-receptor pair. Considering the well-established function
of CXCR7 as a decoy receptor, we predicted that expression levels of Cxcr7 may
homeostatically increase under conditions of increased AM peptide. To further evaluate
whether this interaction exists, we measured the expression of Cxcr7 in hearts of Admhi/hi
mice which have a genetically engineered, 3-fold increase in Adm gene expression (Wetzel-
Strong et al., 2013). Indeed, utilizing qRT-PCR, we identified a potent 2.5-fold upregulation
of Cxcr7 gene expression in Admhi/hi cardiac tissue compared to that of wildtype littermates
(Figure 1A). Conversely, loss of Adm expression in isolated endothelial cells resulted in a
nearly 5-fold reduction in Cxcr7 expression (Figure 1A).
We also found that Cxcr7 is expressed at high levels in isolated, adult lymphatic vessels—a
tissue where AM peptide plays important roles (Figure S1A). Consistently, microarray
analysis of cultured, human lymphatic endothelial cells (LECs) showed that expression of
the human CXCR7 gene (aka ACKR3 or CMKOR1) was one of the ten most significantly
induced genes within 1 hour of 10nM AM treatment (p=2.5E-07) (Figure 1B and Table
S1). This finding was further confirmed by qRT-PCR, revealing a 4-fold increase in CXCR7
gene expression following 1- and 24- hours of AM treatment (Figure 1C). Pretreatment
with AM22-52, a CLR/R2 antagonist, significantly reduced this AM-mediated increase
(Figure 1C), demonstrating that the upregulation of CXCR7 gene expression is modulated
through the canonical AM receptor. Collectively, these data indicate that CXCR7 and ADM
gene expression levels are coupled within tissues where AM peptide plays important
developmental and physiological roles. Since excess AM, either by genetic overexpression
in vivo or exogenous treatment in vitro, triggered an increase in CXCR7 expression, we next
tested directly the hypothesis that CXCR7 serves as a decoy receptor to modify AM
concentration.
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CXCR7 scavenges AM peptide and dampens canonical AM signaling
Using a classical scavenger assay, CXCR7-expressing HEK293T cells were treated with
biotinylated-AM1-52, and aliquots of media were collected over time to determine the
remaining levels of AM peptide within the media. While the levels of biotinylated-AM1-52
in the media of vector-transfected control cells remained unchanged, CXCR7-expressing
cells rapidly and steadily depleted AM peptide from the media to levels that were
statistically lower than control cells by the conclusion of the time course (Figure 1D, E).
These data demonstrate the ability of CXCR7 to modulate AM ligand concentrations
exogenously in a controlled in vitro system.
To determine whether this scavenging of AM peptide by CXCR7 was conserved in vivo, we
compared AM staining in cardiac tissue of wildtype mice and Cxcr7−/− mice, which harbor
an insertional GFP reporter within the targeted allele. Firstly, we noted that expression of the
GFP reporter was enriched within the epicardium and the endocardium surrounding the
trabeculae and weakly expressed in the compact zone (Figure 1F). Secondly, the staining
pattern of receptor expression was spatially juxtaposed and/or overlapping with the most
prominent sites of AM peptide expression, including the epicardium and trabeculae (Figure
1G and (Wetzel-Strong et al., 2013)). Remarkably, we found a significant 30% increase in
the relative staining intensities of AM peptide in the epicardium and trabeculae of Cxcr7−/−
mice compared to wildtype littermates (Figure 1H-K), but no changes within the compact
zone where levels of Cxcr7 reporter expression were modest (Figure 1L). These findings
indicate that spatially juxtaposed and/or overlapping expression of CXCR7 and AM during
cardiac development is essential for scavenging AM peptide in cardiac tissue in vivo.
Activation of the canonical AM-receptor complex, CLR and receptor activity modifying
protein 2 (RAMP2), elicits an increase in cAMP and subsequent downstream activation and
phosphorylation of ERK (Fritz-Six et al., 2008). Utilizing a highly-sensitive
bioluminescence resonance energy transfer (BRET) reporter system (Barak et al., 2008;
Ponimaskin et al., 2007), we found that HEK293 cells that overexpress CXCR7 failed to
accumulate cAMP upon AM stimulation—a finding consistent with the lack of G-protein
coupling by decoy receptors (Figure S1B). As expected, AM treatment of CLR/RAMP2-
expressing cells resulted in a potent accumulation of cAMP (Figure S1B) and pERK:tERK
upregulation (Figure 1M, N and Figure S1C). Importantly, while AM did not elicit a
pERK:tERK upregulation in cells transfected with CXCR7 alone, the CLR-RAMP2
mediated activation of pERK:tERK was markedly abrogated when cells were co-transfected
with CXCR7 (Figure 1M, N). These in vitro signaling assays demonstrate that CXCR7 can
act as a cell-autonomous molecular rheostat to dampen canonical AM pERK:tERK
signaling.
The effects of CXCR7 on dampening pERK:tERK signaling were also confirmed in vivo,
where we noted significant accumulation of pERK staining in dermal lymphatic vessels of
postnatal day 1 Cxcr7−/− tail skin compared to wildtype littermates (Figure S2A-D).
Furthermore, we also observed a significant increase in the pERK staining in the lymphatic
sac of e13.5 Cxcr7−/− embryos compared to wildtype animals (Figure S2E-J). These in vivo
data from a genetic loss-of-function model aptly reciprocate the findings from the in vitro
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gain-of-function experiments and furthermore demonstrate that loss of Cxcr7 expression
influences ERK phosphorylation on a tissue level.
CXCR7 is dynamically expressed in lymphatic endothelium during development
Previous studies have reported that nearly one third of adult dermal lymphatic vessels
express CXCR7 (Neusser et al., 2010), but the spatiotemporal expression of CXCR7 during
developmental lymphangiogenesis has yet to be described. Using the GFP-targeted Cxcr7+/−
reporter allele, we found Cxcr7 expression co-localized with the lymphatic makers LYVE1
(Figure 2A-C), Prox1 (Figure 2G-I) and podoplanin (Figure 2I-L). At e11.5, lymphatic
progenitor cells are arranged in a stereotypically-polarized fashion within the jugular vein
(JV) and express Cxcr7 (Figure 2D-F, white arrows, Figure 2G, H). Interestingly, we often
noted that Cxcr7 expression is temporarily reduced as the lymphatic progenitors begin to
migrate away from the JV (Figure 2F, I asterisks)− underscoring the dynamic expression of
the decoy receptor in areas of active cell migration. As lymphatic cells coalesce to form the
lymph sacs (LS) between e11.5-e13.5, Cxcr7 was again expressed in some lymphatics,
which were identified by LYVE1 and podoplanin co-labeling (Figure 2J-O). Cxcr7 was
also persistently expressed in the JV cells directly adjacent to the LS (Figure 2P-R, white
arrowheads), consistent with recently published studies demonstrating a paracrine function
for decoy receptors (Moissoglu et al., 2014; Venkiteswaran et al., 2013). In summary, Cxcr7
is highly and dynamically expressed within lymphatic progenitors and early lymphatic
vessels at the time of nascent lymphangiogenesis, which also spatiotemporally correlates
with the proliferative effects of AM during lymphatic development.
Cxcr7−/− mice have enlarged, blood filled lymphatic sacs
We have previously established that AM signaling is required for normal LEC proliferation
at e13.5 (Fritz-Six et al., 2008). Thus, we investigated whether loss of Cxcr7, which we
hypothesize to be a molecular rheostat for AM, disrupts lymphangiogenesis at this point
during embryogenesis. Indeed, approximately 10% of Cxcr7−/− mice exhibited visible
interstitial edema upon dissection at midgestation (Figure 3A, white arrows, Figure 3B, C,
black arrows). Histological evaluation further revealed that approximately 10-15% of
Cxcr7−/− mice displayed interstitial edema, particularly within the thoracic regions
surrounding the developing jugular lymphatics. Additionally, we noticed abnormal LS
morphology, including markedly enlarged and dysmorphic LS in Cxcr7−/− embryos
compared to wildtype littermate embryos (Figure 3D-F). Utilizing computerized
morphometry to calculate LS and JV area, we found that the LS:JV ratio of null mice was
increased 4-fold compared to Cxcr7+/+ mice (Figure 3G). Some sections revealed failure of
the LS to separate from the JV, with prominent platelet thrombi (Figure 3F, black arrows).
Moreover, Cxcr7−/− lymphatic vessels exhibited remarkable blood (Figure 3E, asterisks)
and proteinaceous deposits (Figure 3E, arrowheads), which are phenotypes commonly
ascribed to pathologic lymphangiogenesis and lymph stasis in several mouse models
(Bertozzi et al., 2010; Murtomaki et al., 2013). A scoring rubric to assess the severity of
lymphatic defects showed that LS of Cxcr7−/− embryos had significantly more blood and
protein accumulation compared to control mice (Figure 3H, I). Taken together these results
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demonstrate that loss of Cxcr7 during embryonic development results in aberrant LS
formation.
To determine whether the blood accumulation in the LS was due to improper development
or structure of the lymphovenous valves, we stained frontally sectioned embryos with the
lymphatic markers Prox1 and podoplanin. We observed no structural differences between
Cxcr7+/+ and Cxcr7−/− lymphovenous valves (Figure S3A, B), with both wildtype and
mutant animals exhibiting characteristic high-Prox1 staining on the valve leaflet. We next
considered whether the blood accumulation in Cxcr7−/− lymph sacs might be associated with
precocious development of the lymphatic sac. As expected, e11.5 wildtype embryos
exhibited polarization of LYVE1+ lymphatic progenitors within the jugular vein. However,
some Cxcr7−/− littermate embryos exhibited premature migration of LECs from the jugular
vein and precocious formation of enlarged, blood-filled lymph sacs (S3C, D)—a process
that typically occurs 1-2 days later in development. Thus, we reasoned that the likely cause
of blood accumulation in the Cxcr7−/− mutants is precocious lymph sac formation prior to
proper separation of the blood and lymphatic vascular systems.
Loss of CXCR7 enhances LEC migration in vivo and in vitro
We next sought to determine whether loss of Cxcr7 affected lymphangiogenesis in other
lymphatic vascular beds. At e18.5, staining of Cxcr7−/− cardiac tissue revealed increased
LYVE1+ vessels on the surface of the heart (Figure 4A). This increase might be expected
due to the cardiac hyperplasia in Cxcr7−/− embryos. Nevertheless, when normalized to total
surface area of the heart, null animals exhibited a 20% increase in cardiac lymphatic vessels
on the ventral surface of the heart (Figure 4B). Higher power examination of the cardiac
lymphatic vessels of Cxcr7−/− animals revealed a disruption of branching complexity and
lacunae number (Figure S4A-F), as well as an extensive network of lymphatic vessels in the
curvature of the outflow tract on cardiac dorsal-surface (Figure S4C, arrows) which were
not present in wildtype mice. Additionally, these LYVE1+ vessels tended to extend farther
down the apex of the heart in Cxcr7−/− embryos, suggesting that Cxcr7 also affects LEC
migration (Figure 4A, C).
To elucidate whether loss of CXCR7 is directly involved in enhancing AM-mediated
downstream signaling pathways and cellular migration, we utilized shRNA lentiviral vectors
to achieve 80% knockdown of CXCR7 in human neonatal-LECs (Figure 4D). We first used
a scavenger assay to confirm that CXCR7 shRNA-infected LECs scavenged less AM than
control cells, resulting in increased AM available to interact with the signaling receptor,
CLR/R2 (Figure S5A, B). Next, we showed that knockdown of endogenous CXCR7 in
LECs results in an increase in AM-mediated ERK phosphorylation, with CXCR7 shRNA-
infected LECs exhibiting a potent upregulation in pERK:tERK ratios in response to AM
treatment, whereas control cells did not (Figure S5C).
These CXCR7 knockdown cells were then used to evaluate whether loss of CXCR7
enhances AM-mediated LEC migration. Using an in vitro scratch assay, we showed that AM
promotes LEC migration, since AM-treated control cells migrated 41% more than vehicle-
treated cells (Figure 4E, G). On the other hand, AM treatment of CXCR7 knockdown cells
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caused the cells to migrate into the scratch 66% more than vehicle-treated cells (Figure 4F,
H). Moreover, percent migration of AM-treated CXCR7 knockdown LECs was significantly
increased above all other conditions (Figure 4I). These scratch assay findings were fully
recapitulated using a transwell migration assay (Figure 4J). Finally, the effect of CXCR7 on
AM-mediated cell migration was corroborated using an overexpression model. As expected,
AM treatment of CLR/RAMP2-expressing HEK293T cells resulted in increased migration
across a transwell. However, this migration was abrogated when cells were co-transfected
with a CXCR7 expression plasmid (Figure 4K). Collectively, these data show that CXCR7
expression modulates AM-mediated downstream signaling activity, with knockdown of
endogenous CXCR7 increasing and overexpression of CXCR7 reducing AM-mediated
cellular migration.
Dermal lymphatic vessels of Cxcr7−/− animals are enlarged, with less branching
complexity
We also observed morphological changes in the dermal lymphatic vessels of Cxcr7−/− mice.
Interestingly, although there was stochastic expression of Cxcr7 in dermal lymphatic vessels
(Figure S6), we consistently observed Cxcr7 expression in blood vessels, again suggesting
that non-cell autonomous expression of Cxcr7 can affect lymphangiogenesis. While the
dermal lymphatics of wildtype animals formed a highly-structured lattice network, those of
Cxcr7−/− embryos failed to extend and connect to neighboring vessels, resulting in fewer
ring-like structures or lacunae (Figure 5A, B asterisks). For example, control lymphatic
capillary networks comprised between 6-8 lacunae per image, but the lymphatic network of
Cxcr7−/− skin consisted of only 4-5 lacunae per image (Figure 5C). Quantitation of the
number of branch points also revealed a significant reduction in branching complexity, from
23.2 to 16.3 per image, between control and Cxcr7−/− dermal lymphatics (Figure 5D).
(Image area measured 132800 μm2.) Additionally, Cxcr7−/− dermal lymphatic vessels were
enlarged compared to littermate controls (Figure 5E-I, yellow dashed line). The junctional
area where vessels coalesce to form a branch point was also increased (Figure 5G, H, J
yellow solid line).
Previously published studies demonstrate that this type of increase in vessel diameter and
decreased branching complexity is consistent with a hyperplastic phenotype (Coxam et al.,
2014; James et al., 2013), suggesting that loss of CXCR7 results in hyperproliferation of
LECs. We therefore sought to determine if this hyperplastic phenotype of Cxcr7−/− dermal
lymphatics could be attributed to increased AM-mediated LEC proliferation—a biological
effect of AM which has been demonstrated by our group and others (Fritz-Six et al., 2008;
Jin et al., 2008; Karpinich et al., 2013). Using CXCR7 knockdown LECs, we observed a
50% increase in proliferation in AM-treated CXCR7 knockdown LECs compared to AM-
treated control cells (Figure 5K). Collectively, these data demonstrate that loss of CXCR7
promotes AM-mediated LEC lymphangiogenesis by enhancing both migration and
proliferation in vivo and in vitro.
Genetic titration of Adm changes Cxcr7−/− survival
We next sought to determine whether the phenotypes of Cxcr7−/− embryos could be causally
associated with AM ligand concentration in vivo. To test this, we employed a genetic
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approach, depicted in Figure 6A, C, which allowed for the generation of Cxcr7 gene-
targeted mice on a titrated background of AM ligand that ranges from 50% to 300%
wildtype levels. Adm+/− mice express 50% of wildtype levels of Adm mRNA and peptide
and exhibit exacerbated cardiovascular damage, reduced female fertility, and defective
lymphatic function (Caron and Smithies, 2001; Li et al., 2006; Nikitenko et al., 2013).
Admhi/hi animals survive to adulthood, but exhibit profound cardiac hyperplasia during
development (Wetzel-Strong et al., 2013). Therefore, we were confident that the effective
dosage of AM peptide achieved with the AM “gene titration” mice was within a range that
would have significant biological impact on lymphatic and cardiac development.
First, because we noted some embryonic lethality in Cxcr7−/− animals in the genetic
reduction experiment, we asked whether Adm haploinsufficiency might improve Cxcr7−/−
embryo survival during mid-gestation. At e13.5 we observed equivalent numbers of
Cxcr7−/−;Adm+/+ and Cxcr7−/−;Adm+/−animals from compound heterozygous intercrosses
(Figure 6B, e13.5). However, at e14.5 the expected 1:1 ratio of Cxcr7−/−; Adm+/+:Cxcr7−/−;
Adm+/− mice was significantly skewed, with less than 50% of the expected Cxcr7−/−;
Adm+/+ genotype being offset by a disproportionate survival of Cxcr7−/−;Adm+/− embryos
(Figure 6B, e14.5). Thus, haploinsufficiency of Adm improves Cxcr7−/− embryo survival
during mid-gestation. It is also noteworthy that embryonic lethality was significantly
increased in the Cxcr7+/−;Adm+/− cross, which is likely due to the critical role of AM in
female reproductive physiology (Lenhart and Caron, 2012; Lenhart et al., 2014; Li et al.,
2013; Li et al., 2008; Li et al., 2006). This finding suggests that disruption of the parental
CXCR7-AM axis likely contributes to the severity of the phenotypes.
Next, we bred Cxcr7+/− mice to Admhi/hi animals in order to evaluate whether AM
overexpression might exacerbate Cxcr7−/− gestational loss or influence survival.
Interestingly, we found that postnatal survival of compound heterozygous pups was poor,
with nearly 30% postnatal lethality, making maintenance of the Cxcr7+/−;Admhi/+ mouse
colony very challenging. Whereas we had not previously observed Cxcr7+/− pup lethality in
other genetic crosses, Cxcr7+/− animals that expressed a single Admhi allele were more
susceptible to death. Moreover, homozygosity for the Admhi allele resulted in a striking 65%
lethality of Cxcr7+/−;Admhi/hi mice (Figure 6D). Collectively, these data demonstrate that
titration of the endogenous AM ligand is causally associated with profound changes in the
survival of Cxcr7 gene targeted animals.
Haploinsufficiency of AM normalizes lymphatic and cardiac hyperproliferation of Cxcr7−/−
mice
Based on the improved embryonic survival of Cxcr7−/−;Adm+/− embryos, we next
performed phenotypic characterization of lymphatic and cardiac development in these
animals, with the expectation that haploinsufficiency for AM ligand might normalize the
hypertrophic cardiovascular phenotypes of Cxcr7 null embryos. Importantly,
haploinsufficiency of AM had no effect on the LS:JV ratio in Cxcr7+/+ animals (Figure 6E,
F). Consistent with Figures 3E-G, the podoplanin-positive lymph sacs of e13.5
Cxcr7−/−;Adm+/+ embryos showed a significant 4-fold enlarged LS:JV ratio compared to
wildtype littermates (Figure 6G, I). However, this lymph sac enlargement was normalized
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in Cxcr7−/−;Adm+/− mice, resulting in LS:JV ratios that were statistically indistinguishable
from wildtype animals (Figure 6H, I). Additionally, we used Ki67 staining to quantitate the
number of proliferating LECs and found a direct correlation between the proliferation of
LECs and the LS:JV ratios and genotypes. While Cxcr7−/−;Adm+/+ mice had significantly
more proliferating cells in the LS compared to wildtype animals (Figure 6G, J),
haploinsufficiency for AM (Cxcr7−/−;Adm+/−) allowed this hyperproliferation to revert to
levels that were equivalent to those observed in wildtype animals (Figure 6H, J). Taken
together, these findings demonstrate that the increase in LS:JV ratio in CXCR7 null mice is
due to an increase in LEC proliferation which can be reversed by genetic reduction of AM
ligand.
Similar effects were observed in the developing heart. Using BrdU incorporation assays, we
quantitated the amount of proliferating cells in e11.5 cardiac tissue from the AM genetic
titration animals. Percent proliferation of cardiac cells in Cxcr7+/+;Adm+/− animals was
equivalent to wildtype animals, demonstrating that Adm haploinsufficiency alone does not
affect heart size (Figure 7A-D). Consistent with other studies (Gerrits et al., 2008), we
noted a statistically significant increase in proliferation of Cxcr7−/− cardiac tissue compared
to wildtype (Figure 7E, F, I). Importantly, this aberrant cardiac hyperproliferation was
normalized to wildtype levels in Cxcr7−/−;Adm+/− embryos (Figure 7G, H, I). We noted
increased proliferation particularly within the epicardium and trabeculae (Figure 7F-H,
arrows and arrowheads respectively)--regions of the heart where CXCR7 is highly expressed
(see Figure 1F). Furthermore, 2 days after the AM-mediated peak in myocyte proliferation,
many of the hearts of Cxcr7−/−;Adm+/− embryos appeared phenotypically normal and
similar in size to wildtype animals (Figure 7J-L). We therefore conclude that genetic
reduction of AM peptide alleviates the pathological cardiac hyperproliferation of Cxcr7 null
animals and ultimately impacts cardiac size during development.
Though difficulty maintaining the line precluded extensive timed matings, we observed even
more precocious development of the LS of Cxcr7−/−;Admhi/hi embryos. At e11.5,
Cxcr7−/−;Admhi/hi embryos often had fully formed lymph sacs that were dramatically
enlarged, and blood filled (Figure S3E). This further exacerbated lymphatic development
confirmed our hypothesis that Cxcr7−/− LS develop precociously. Hearts of Cxcr7−/− on the
Admhi/hi background also tended to be enlarged with thickened compact zones and
significant blood accumulation in the ventricles and atria (data not shown).
Discussion
The pleiotropic consequences of CXCR7 loss have made it difficult to discern which
ligand(s) are responsible for a given phenotype. In this study, using both loss-of-function
and gain-of-function animal models, we demonstrate that several of the essential functions
of CXCR7 during cardiovascular development can be attributed to its decoy activities for the
ligand, AM. Haploinsufficiency of AM in a Cxcr7−/− animal effectively reversed cardiac
and lymphatic hyperproliferation, demonstrating that CXCR7 is required as a molecular
rheostat for controlling AM ligand availability during development. While other atypical
chemokine receptors are known to bind multiple ligands, only recently has the repertoire of
CXCR7 ligands been expanded beyond the chemokines CXCL12 and CXCL11. For
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example, a very recent study has elegantly demonstrated that proteolytic peptide fragments
of the adrenal neuropeptide proenkaphalin A interact with CXCR7 and thereby mediate
responses to glucocorticoid secretion and anxiety behaviors in mice (Ikeda et al., 2013).
Structure-function studies of the proenkaphalin A-derived peptides, along with our current
findings on the AM peptide, further highlight the ability of CXCR7 to bind to several classes
of small peptidergic ligands, which also happen to be particularly enriched in the adrenal
gland. Whether adrenomedullin—which as it name implies, is also highly expressed in the
adrenal gland—is also implicated in the CXCR7-mediated glucocorticoid secretion and
anxiety behaviors has yet to be determined.
Likewise, our study does not formally rule out the involvement of CXCL12 in the described
cardiovascular hyperplasia phenotypes of Cxcr7−/− mice. Genetic deletion of either CXCR4
or CXCL12 has been associated with defective ventricular septum formation (Ma et al.,
1998; Zou et al., 1998). However, only recently have studies in chick embryos demonstrated
a gain-of-function phenotype for CXCL12 overexpression in neural crest cell migration
related to cardiac development (Escot et al., 2013). While the effects of CXCL12
overexpression might be anticipated to more closely parallel the effects of CXCR7 loss-of-
function, the cardiac phenotypes of these two models are markedly different. CXCL12 mis-
expression in chick embryos diverts neural crest cell migration to the heart, while CXCR7
deficiency promotes cardiac myocyte hyperplasia and septal defects. Our current study does
not preclude the functional deregulation of CXCL12, however it does definitively
demonstrate that genetic reduction in AM ligand is fully sufficient to rescue the Cxcr7−/−
cardiac hyperplasia. Therefore, although we cannot exclude potential effects of CXCL12 on
the Cxcr7−/− cardiac phenotypes, we have identified AM as the critical ligand for mediating
the cardiac hyperproliferation.
With respect to lymphangiogenesis, genetic studies in zebrafish have also established a
central role for CXCL12(SDF-1)/CXCR4 signaling during the stepwise assembly of the
lymphatic trunk network (Cha et al., 2012). Interestingly, the requirement for CXCL12 in
guiding zebrafish LEC migration occurs at developmental time points that are subsequent to
LEC sprouting from the posterior cardinal vein. However, our expression studies in mice
revealed little expression of CXCR7 in LECs that have migrated away from the jugular vein,
and we failed to observe prominent defects in the migration and assembly of lymphatic sacs
in Cxcr7−/− mice. Although these spatiotemporal differences in receptor-ligand expression
patterns may simply be attributed to differences between species, a more compelling
implication of these studies is that dynamic changes in the expression of CXCR4 and
CXCR7 may be critical for orchestrating the extent and time frame to which nascent LECs
sense and respond to different lymphangiogenic growth factors. Moreover, the dynamic
spatiotemporal expression of signaling and decoy receptors likely provides a mechanism for
individual LECs and their adjacent tissues to create a localized microgradient of chemotactic
or proliferative factors (Dona et al., 2013; Venkiteswaran et al., 2013) to promote the
stepwise growth of lymphatic vessels.
Although our current study has focused on the effects of CXCR7 on AM-mediated cardiac
and lymphatic development, it is important to recognize that the interaction of CXCR7 with
AM may initiate downstream signaling and active processes in other cell types or tissues.
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For example, several studies have pointed to potential non-decoy functions of CXCR7, such
as signaling through ß-arrestin, heterodimerizing with other GPCRs in certain tissues, and
coupling with G-proteins in astrocytes (Kapas and Clark, 1995; Odemis et al., 2012;
Rajagopal et al., 2010). Therefore, while we have currently established CXCR7 as a
molecular rheostat for AM signaling during cardiovascular development, future studies may
identify potential CXCR7-GPCR complexes that allow for functional AM signaling in other
cell types or tissues.
Our findings of increased ERK phosphorylation in dermal lymphatics of Cxcr7−/− mice are
consistent with several previously described models with aberrant lymphangiogenesis
associated with increased ERK signaling. For example, ex vivo expression of Spred-1/2,
negative regulators of ERK activation, suppresses LEC proliferation while double knockout
mice exhibit dilated, blood-filled lymphatics— similar to the Cxcr7−/− phenotype described
here (Taniguchi et al., 2007). Likewise, mice lacking apopotosis stimulating protein of p53
(Aspp1) have increased ERK activation and exhibit similar transient subcutaneous edema
with dilated and dysmorphic lymphatics and increases in cardiac LYVE1+ staining
(Hirashima et al., 2008). Most recently, a fine-tuned balance between ERK and Akt
signaling pathways has been recognized as an essential component for establishing LEC fate
determination and differentiation (Deng et al., 2013; Simons and Eichmann, 2013).
Collectively, these studies identify ERK signaling as a critical regulator of
lymphangiogenesis and either loss or excessive ERK signal as a cause of aberrant
lymphangiogenesis. Results of this study identify a mechanism, whereby the positioning of a
decoy receptor at the junction of lymphatic sprouting and migration serves as a biological
rheostat for regulating the migratory and mitogenic effects of lymphangiogenic growth
factors that are upstream of ERK activation. Additional studies to determine whether and
how other atypical chemokine receptors may influence cardiac and lymphatic development
are warranted and may lead to conceptual paradigms about how growth factor gradients and
their downstream signaling pathways can be precisely controlled by 7-transmembrane decoy
receptors during cardiovascular development.
Experimental Procedures
Mice
Mice that contain a GFP reporter knocked into the Cxcr7 gene were purchased (C57BL/6-
Ackr3tm1Litt/J, The Jackson Laboratory). Generation of Adm+/− and Admhi/hi mice with a
targeted, deletion and overexpression of Adm, respectively, has been previously described.
(Caron and Smithies, 2001; Dackor et al., 2006; Li et al., 2013). For timed pregnancies,
Cxcr7+/− animals were intercrossed with Cxcr7+/− or Cxcr7+/−;Adm+/− animals. Dams
were monitored for vaginal plugs, and the day when the vaginal plug was detected was
considered E0.5. Cxcr7+/−;Admhi/+ animals were also intercrossed to establish survival. For
BrdU incorporation assays, pregnant females were injected with BrdU (0.1 mg/g of BW,
Sigma-Aldrich) via intraperitoneal injection two hours prior to dissection. All experiments
involving mice were approved by the Institutional Animal Care and Use Committee at the
University of North Carolina at Chapel Hill.
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Cell culture and RNAi
Human adult (HMVECdLyAd-Der) and neonatal (HMVEC-d Neo) dermal lymphatic
endothelial cells (Lonza) were cultured in EGM-2MV media. HEK293T cells were
maintained in DMEM with 10% fetal bovine serum and 1% penicillin streptomycin or
gentamicin. Lentiviral particle production and infection were performed according to
standard protocol. Briefly, human CXCR7 shRNA pLKO1 vectors (UNC Viral Core) were
co-transfected into HEK293T cells with lentiviral packaging vectors psPAX2 and MD2.G
(Addgene) using Lipofectamine 2000 (Invitrogen). Viral supernatants were filtered,
supplemented with 6ug/mL polybrene, and used to infect LECs for 48 hours before
functional assays were performed.
Gene Expression Analysis
Agilent human gene expression microarrays were performed on three independent plates of
hLECs treated with 10nM AM (American Peptide Company). Analysis was performed using
the Significance Analysis of Microarrays (SAM) software (Stanford University). For
embryonic endothelial cells, CD31 positive cells were isolated using magnetic beads.
Quantitative RT-PCR was performed using primers and probes or hCXCR7 Assays on
Demand (Life Technology) after reverse transcription of 2 μg of total RNA. For AM22-52
treatment, cells were incubated with 1μM AM22-52 (American Peptide Company) for 30
minutes prior to treatment with 10nM AM and 1μM AM22-52.
Scavenger assay
HEK293T cells were transfected with CXCR7 or pcDNA3.1 (negative control) using
standard calcium phosphate transfection. Cells were treated with biotinylated-AM (Phoenix
Pharmaceuticals), and aliquots of media were collected over 8 hours. Biotinylated-AM was
detected with IRDye Streptavidin (1:2500, Li-COR).
ERK phosphorylation
HEK293T cells were transfected with expression plasmids, serum starved for 20 hours, and
treated with vehicle or 10nM AM for 1 minute. Blots were blocked in 5% BSA, probed
overnight with monoclonal rabbit anti-mouse pERK and tERK (1:1000, Cell Signaling) and
monoclonal mouse anti-GAPDH (1:2000, Novus Biologicals), incubated in appropriate
secondary antibody, and imaged on the Odyssey scanner (Li-COR). A blot with 3
independent experiments run on the same gel was used to perform statistical analysis.
Immunohistochemistry
Embryo sections and whole mount tissue were permeabilized, blocked with 5% normal
donkey serum, and incubated overnight at room temperature with primary antibodies, and
then probed with appropriate secondary antibodies. Antibodies are described in the
supplemental experimental procedures.
Quantitation of LS:JV ratio and Blood and Protein Accumulation in LS
Transverse sections of jugular lymph sacs of wildtype and mutant mice were H&E stained.
The area of the LS and JV were measured using ImageJ software (NIH), and sections were
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graded for blood and protein accumulation in the LS using a scoring rubric. Blood and
protein were graded as follows: 0 = no red blood cells (RBC); 1 = 3-10 RBC; 2 = 3-50
RBCs; 3 = >50 RBCs; 0 = no protein; 1 = minimal protein accumulation; 2 = moderate
protein accumulation; 3 = extensive protein accumulation. Brightfield images were taken on
a Leitz Dialux 20 Micrscope.
In vitro Migration and Proliferation Assays
Scratch assay—CXCR7 knockdown (and negative control) LECs were grown to
confluence and then scratched with a pipette tip. LECs were rinsed with PBS to remove non-
adherent cells and then treated in 0.5% FBS RPMI with vehicle or 10nM AM. Four fields
per well were imaged at T=0 hrs and at T=18hrs post-scratch using an Olympus IX-81
inverted microscope equipped with a QImaging Retiga 4000R camera at 4X magnification.
The percent change in migration was calculated by measuring the open area of the scratch
(ImageJ). Results shown are representative of three independent experiments.
Transwell migration assay—HEK293T cells transfected with expression plasmids and
LECs with lentiviral induced CXCR7 knockdown were labeled with 5μM Cell Tracker
Green (CTG) CMFDA (Life Technologies). Cells (1×105) were treated with 10nM AM for 5
min and then seeded onto 8μm transwell inserts (BD Biosciences). After 4 hour incubation,
inserts were fixed with 4% PFA, and filters were mounted for analysis. Quantification of
transmigrated cells was done by measuring the threshold of CTG-labeled cell fluorescence
using ImageJ (NIH).
Proliferation—CXCR7 knockdown and scramble LECs were plated, serum starved for 4
hours, then treated with 10nM AM for 24 hours. Cells counts were assessed using a
Countess Automated Cell counter (Life Technology).
Statistical Analysis
Student's two-tailed t test was used for all comparisons unless otherwise noted in the figure
legend.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Adrenomedullin (AM) is a biological ligand for CXCR7
• CXCR7 scavenges AM peptide and dampens AM-mediated pERK, in vitro and
in vivo
• Dynamic expression of CXCR7 is required for proper lymphangiogenesis
• Genetic reduction of AM reverses lymphatic and cardiac hyperplasia of
Cxcr7−/− mice
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Figure 1. CXCR7 scavenges AM, dampens AM-mediated ERK phosphorylation in vitro, and
reduces AM peptide levels in vivo
(A) Cxcr7 expression in cardiac tissue of Adm+/+ and Admh/hi mice (n=6) and isolated
endothelial cells of Adm+/+ and Adm−/− mice (n=3)
(B) The nine most significantly upregulated and four most significantly downregulated
genes in human LECs (hLECs) treated with 10nM AM for 1 hour.
(C) CXCR7 expression in vehicle and 10nM AM treated hLECs at 15m, 1h and 24h, and
AM22-52, AM, and [AM22-52+AM] for 4 hr.
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(D) Representative western blots probed for biotin and (E) quantitation of biotinylated-
AM1-52 depletion over 8 hours by either CXCR7 or EV expressing cells in three
independent experiments.
(F,G) Cxcr7 and AM staining in e13.5 Cxcr7−/− cardiac tissue with epicardial colocalization
(white arrows).
(H,I) AM staining of e13.5 Cxcr7+/+ and Cxcr7−/− cardiac tissue. White arrows highlight
epicardium, CZ identifies the compact zone, and white arrowheads highlight the cardiac
trabeculae. Images were obtained at the same exposure and the amount of AM expressed in
the three regions of the heart was assessed by measuring the integrated density of staining
using Image J software (n=3-5). Scale bars, 100 μM.
(J-L) Quantitation of AM staining intensity in Cxcr7+/+ (n=3) vs. Cxcr7−/− (n=5) animals in
3 regions of the heart, trabeculae, epicardium, and compact zone. Staining intensity is
expressed as arbitrary units of integrated density measured by ImageJ.
(M) Representative western blot and (N) quantitation of change in pERK:tERK between
vehicle and 10nM AM treated CXCR7-, CLR/R2-, and CLR/R2+CXCR7-expressing
HEK293T. Quantitation was calculated using 3 independent experiments run on the same
gel.
In (A-L), data are represented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.
See also Figures S1, S2, and Table S1.
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Figure 2. Cxcr7 is dynamically expressed in lymphatic endothelium during development
(A-C) Cxcr7 and LYVE1 colocalize in the JV of e11.5 Cxcr7+/− animals.
(D-F) Higher magnification of the LYVE1 positive portion of the JV. White arrows
highlight areas of Cxcr7 and LYVE1 colocalization. Asterisk highlights migrating LYVE1
positive, Cxcr7 negative cells. (G-I) Cxcr7 and Prox1 colocalize in the JV of e11.5 Cxcr7+/−
animals. Asterisks highlight migrating Prox1 positive, Cxcr7 negative cells LECs.
(J-O) Cxcr7 and lymphatic markers (J, podoplanin; M, LYVE1) colocalize in the LS (white
arrows) of e11.5 (J-L) and e13.5 (M-O) Cxcr7+/− animals.
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(P-R) Cxcr7 is also expressed in cells of the JV directly adjacent to the LS. White
arrowheads highlight Cxcr7 expression in the JV. Scale bars, 50 μM.
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Figure 3. Cxcr7−/− embryos have enlarged blood filled lymphatic sacs and interstitial edema
(A-C) Some Cxcr7−/− embryos exhibit interstitial edema at e13.5 (white (A) and black (C)
arrows).
(D-F) Cxcr7−/− embryos exhibit enlarged lymph sacs filled with blood (asterisks) and
proteinaceous deposits (arrowheads) at e13.5.
(F) In some Cxcr7−/− embryos, the LS fails to separate from the JV properly. Platelet
thrombi are highlighted by arrowheads.
(G-I) Quantitation of the LS:JV ratio (t test) and blood and protein accumulation (Mann-
Whitney U test) in the LS of Cxcr7−/− embryos (n=10) compared to wildtype controls (n=5).
A detailed description of the scoring rubric is provided in the methods section. Data are
represented as mean ± SEM. *p<0.05, **p<0.01.
See also Figure S3.
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Figure 4. Loss of CXCR7 enhances cardiac lymphangiogenesis by promoting AM-mediated
cellular migration
(A) View of ventral side of whole mount hearts of e18.5 embryos stained with the lymphatic
marker LYVE1.
(B,C) Quantitation of LYVE1 staining normalized to surface area (B) and LEC migration
down the apex of the hearts (C) (n=3).
(D) CXCR7 knockdown in LECs by two shRNA lentiviral constructs.
(E-H) Control or CXCR7 knockdown LECs treated with vehicle (E,F) or 10nM AM at 18
hrs (G,H). Migration from the time of scratch (T=0) was measured. Scale bars,100 μM.
(I) Quantitation of LEC migration in CXCR7 knockdown and control LECs.
(J,K) Quantitation of transwell migration of CXCR7 knockdown LECs treated with vehicle
or 10nM AM (J), and empty vector (EV), CXCR7-, CLR/R2-, and CLR/R2+CXCR7-
expressing HEK293T cellstreated with 10nM AM.
Data are represented as mean ± SEM. *p<0.05, **p<0.01.
See also Figure S4 and S5.
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Figure 5. Loss of CXCR7 causes enlarged dermal lymphatics with decreased branching
complexity in vivo and enhances LEC proliferation in vitro
(A,B) Cxcr7−/− P1 skin (n=5) exhibit dysmorphic dermal lymphangiogenesis compared to
controls (n=4). White asterisks identify a lacuna; yellow dots highlight branch points. Scale
bars, 50 μM.
(C,D) Quantitation of the number of lacunae and branch points respectively. Fewer lacunae
and decreased branching complexity were observed in Cxcr7−/− animals. A branch point is
defined as a vessel with 3 vessels branching away. A lacuna is defined as a space where 3 or
more branch points coallesce.
(E-H) Skin of e13.5 Cxcr7−/− embryos. Scale bars, 50 μM.
(I-J) Lymphatic vessels of P1 Cxcr7−/− embryos are dilated, with increased junctional area
where vessels coalesce to form a branch point. Yellow dashed and straight line in (G,H)
represent the vessel diameter and junctional area, respectively, measured in P1 skin.
(K) Quantitation of LEC proliferation after a 24h treatment with 10nM AM.
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In (A-K), data are represented as mean ± SEM. *p<0.05, **p<0.01.
See also Figure S6.
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Figure 6. Genetic titration of Adm influences Cxcr7−/− phenotypes
(A-B) Schematic of Adm genetic reduction experiment with expected and observed
Mendelian ratios. Cxcr7+/−;Adm+/− mice were bred with Cxcr+/−;Adm+/+ mice, resulting in
the following expected distribution: 25% Cxcr7+/+, 50% Cxcr7+/−, and 25% Cxcr7−/− with
50% of each Cxcr7 genotype being AM heterozygous. Observed number of animals was
statistically different from expected as judged by a chi-squared test (p=0.02).
(C-D) Schematic of Adm genetic increase experiment with expected and observed
percentage of survival of animals, n = 85. Observed number of animals (including
resorptions) was statistically different from expected as judged by a chi-squared test
(p=0.001).
(E-H) Representative images of JV and LS of e13.5 embryos from the gene reduction
experiment stained for podoplanin and Ki67. Scale bars, 100 μM.
(I) Quantitation of the LS:JV ratio in e13.5 embryos (n= 4-8 for each genotype).
(J) Percent proliferating cells in the LS (n= 4-8 for each genotype).
Data are represented as mean ± SEM. *p<0.05, **p<0.01 (One-way ANOVA).
Klein et al. Page 26






















Figure 7. Genetic reduction of AM normalizes Cxcr7−/− cardiac proliferation and size
(A-G) (A,C,E,G): BrdU staining of cardiac tissue of e11.5 embryos from the gene titration
experiment. Exposure, 750 ms. Scale bars, 100 μM. (B,D,F,H): Arrows highlight
proliferating epicardium, and arrowheads highlight proliferating endocardium. Exposure,
250 ms. Scale bars, 100 μM.
(I) Percent proliferating cardiac cells in embryos from genetic reduction experiment. (n=3-5
for each genotype). Data are represented as mean ± SEM. *p<0.05 (One-way ANOVA).
(J-L) H&E-stained cardiac tissue of e13.5 animals from the genetic reduction experiment.
(n=3-5 for each genotype). Scale bars, 100 μM.
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